Retatrutide and Alcohol Use Disorder

Retatrutide (LY3437943) is an investigational drug. It is not FDA-approved for any indication, including alcohol use disorder. This page summarizes early preclinical and observational research. Nothing here constitutes medical advice or implies that retatrutide is an established treatment for AUD.

GLP-1 receptors are expressed not only in the pancreas and gut but also in brain regions involved in reward processing, including the ventral tegmental area (VTA), nucleus accumbens, and prefrontal cortex. Preclinical research has shown that GLP-1 receptor activation in these areas can reduce dopamine-mediated reward responses to food, alcohol, and other substances. This is the mechanistic basis for the hypothesis that GLP-1 receptor agonists might reduce alcohol craving and consumption.

Multiple rodent studies have demonstrated that GLP-1 receptor agonists — including exendin-4, liraglutide, and semaglutide — reduce voluntary alcohol consumption in animal models of alcohol use disorder. A 2017 study by Vallöf et al. in Addiction Biology showed that systemic and central administration of exendin-4 reduced alcohol intake in rats. A 2022 study by Farokhnia et al. in JCI Insight found that liraglutide reduced alcohol self-administration in non-human primates. These findings are consistent across multiple labs and animal models, which strengthens the preclinical hypothesis — but animal-to-human translation in addiction research is historically unreliable.

Several retrospective analyses of large insurance and pharmacy databases have found that patients prescribed GLP-1 receptor agonists for diabetes or obesity had lower rates of alcohol-related hospitalizations and diagnoses compared to matched controls. A 2024 analysis published in Nature Communications (Hajduk et al.) examined electronic health records and found associations between GLP-1 agonist use and reduced alcohol use disorder diagnoses. These are observational findings — they cannot establish causation, are subject to confounding, and do not involve retatrutide specifically. No randomized controlled trial has tested any GLP-1 agonist for AUD as a primary endpoint in a large human population.

No published study has examined retatrutide's effects on alcohol consumption or AUD in humans or animals. Retatrutide activates GLP-1 receptors — the same receptor implicated in the preclinical AUD hypothesis — but it also activates GIP and glucagon receptors, whose roles in alcohol reward are less studied. Whether retatrutide's triple-receptor mechanism would produce stronger, weaker, or equivalent effects on alcohol consumption compared to GLP-1-only agonists is unknown. No TRIUMPH trial includes AUD as an endpoint.

Key open questions include: (1) Does GLP-1 receptor agonism reduce alcohol consumption in humans in a randomized controlled trial? (2) Is any effect durable, or does it diminish with tolerance? (3) Does the addition of GIP and glucagon receptor agonism (as in retatrutide) alter the reward-pathway effect? (4) What dose would be required, and would it differ from obesity dosing? (5) Are there safety interactions between retatrutide and alcohol that require study? None of these questions have been answered.